ClinicalTrials.gg
RecruitingNCT04934007ORBITOC3Updated Jan 13, 2026

Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder

An interventional study of rTMS Treatment in Obsessive-Compulsive Disorder, sponsored by Centre Hospitalier Henri Laborit. Recruiting at 2 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Centre Hospitalier Henri Laborit · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Obsessive-Compulsive Disorder with a site in France — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · France.

Planned enrollment
2nd of 18
136 · median 45
Started
2021
the only one that year
No phase
14 of 20
5 open now
Registered
17th of 20
by date
Lead sponsor
4 of 20
Centre Hospitalier Henri Laborit

Among the 20 studies in Obsessive-Compulsive Disorder with a site in France, this one is the 2nd largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2021, is one of 14 with no phase, and was the 17th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

5 of the 20 studies in Obsessive-Compulsive Disorder with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Obsessive-Compulsive Disorder with a site in France, or all of them as a file.
02

Study summary

According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • rTMS
  • D-B80 A/P
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Participants will be both males and females, 18-65 years of age included.
  • diagnosis of OCD
  • all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks
  • Affiliation to a social security system (recipient or assignee),
  • Signed written inform consent form

Exclusion criteria

Exclusion Criteria:

  • The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness
  • In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded
  • The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0.
  • Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable or who is nursing,
  • Patient under curators
  • Patient hospitalized under duress
  • Patient unable to give his or hers
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Active stimulation

    Active rTMS stimulation , 2 session per day during 10 days.

    Device: rTMS Treatment

  • Sham comparator
    Sham Stimulation

    Sham rTMS stimulation , 2 session per day during 10 days.

    Device: rTMS Treatment

Interventions

  • DevicerTMS Treatment

    1 Hz rTMS

06

What researchers measure

Primary outcomes

  1. Yale Brown Obsessive Compulsive Scale score

    Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25

    Time frame: baseline and 25 days

Secondary outcomes

  1. Yale Brown Obsessive Compulsive Scale

    Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70

    Time frame: baseline and 70 days

  2. general assessement functioning (GAF)

    Change of the general assessement functioning (GAF) at day 25

    Time frame: baseline and 25 days

  3. general assessement functioning (GAF)

    Change of the general assessement functioning (GAF) at day 70

    Time frame: baseline and 70 days

  4. Clinical Global Impression (CGI)

    Clinical Global Impressions (CGI) change at day 25

    Time frame: baseline and 25 days

  5. Clinical Global Impression (CGI)

    Clinical Global Impressions (CGI) change at day 70

    Time frame: baseline and 70 days

  6. Adverse events linked to the rTMS treatment

    Number and types of adverse events linked to the rTMS treatment

    Time frame: 70 days

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 72 months is above that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jun 22, 2021
StartActual
Sep 6, 2021
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04934007
Lead sponsor
Centre Hospitalier Henri Laborit
Responsible party
Sponsor
First posted
Jun 22, 2021
Start date
Sep 6, 2021
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Ghina Harika-Germaneau, MD, PhD
Contact
ghina.harika.germaneau@ch-poitiers.fr
+33 5 16 52 61 18
Nematollah Jaafari, PR
Contact
nemat.jaafari@ch-poitiers.fr
+33 5 16 52 61 18
Ghina Harika-Germaneau
study director · Centre Hospitalier Henri Laborit

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion